DE60325016D1 - Oligonukleotide mit alternierenden segmenten und deren verwendungen - Google Patents
Oligonukleotide mit alternierenden segmenten und deren verwendungenInfo
- Publication number
- DE60325016D1 DE60325016D1 DE60325016T DE60325016T DE60325016D1 DE 60325016 D1 DE60325016 D1 DE 60325016D1 DE 60325016 T DE60325016 T DE 60325016T DE 60325016 T DE60325016 T DE 60325016T DE 60325016 D1 DE60325016 D1 DE 60325016D1
- Authority
- DE
- Germany
- Prior art keywords
- oligonucleotides
- sugar
- alternating segments
- alternative segments
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35287302P | 2002-02-01 | 2002-02-01 | |
PCT/CA2003/000129 WO2003064441A2 (en) | 2002-02-01 | 2003-01-31 | Oligonucleotides comprising alternating segments and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60325016D1 true DE60325016D1 (de) | 2009-01-15 |
Family
ID=27663144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60325016T Expired - Lifetime DE60325016D1 (de) | 2002-02-01 | 2003-01-31 | Oligonukleotide mit alternierenden segmenten und deren verwendungen |
Country Status (13)
Country | Link |
---|---|
US (3) | US8278103B2 (de) |
EP (1) | EP1470144B1 (de) |
JP (1) | JP2005522997A (de) |
AT (1) | ATE416183T1 (de) |
AU (1) | AU2003202376B2 (de) |
CA (1) | CA2474414C (de) |
DE (1) | DE60325016D1 (de) |
DK (1) | DK1470144T3 (de) |
ES (1) | ES2318106T3 (de) |
MX (1) | MXPA04007403A (de) |
NZ (1) | NZ534396A (de) |
PT (1) | PT1470144E (de) |
WO (1) | WO2003064441A2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US20050042647A1 (en) * | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
ATE346918T1 (de) * | 1998-06-19 | 2006-12-15 | Univ Mcgill | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide |
US8258288B2 (en) * | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
US20090137510A1 (en) * | 2002-02-20 | 2009-05-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP1857547B2 (de) | 2002-08-05 | 2020-12-02 | Silence Therapeutics GmbH | Weitere neue Formen von interferierenden RNA-Molekülen |
AU2003273336A1 (en) * | 2002-09-18 | 2004-04-08 | Isis Pharmaceuticals, Inc. | Efficient reduction of target rna's by single- and double-stranded oligomeric compounds |
CA2504929C (en) * | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
US9150606B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
CA2569419A1 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
JP5314283B2 (ja) | 2004-10-29 | 2013-10-16 | トピジェン・ファーマシューティカルズ・インコーポレーテッド | アレルギーおよび新生物細胞増殖を治療するための、アンチセンスオリゴヌクレオチド |
EP1937312B1 (de) * | 2005-08-30 | 2016-06-29 | Ionis Pharmaceuticals, Inc. | Chimere oligomere verbindungen zur modulation von splicing |
EP2392645A1 (de) * | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie |
WO2007134451A1 (en) | 2006-05-19 | 2007-11-29 | Topigen Pharmaceuticals Inc. | Oligonucleotides affecting expression of phosphodiesterases |
CA2715289C (en) * | 2008-02-11 | 2019-12-24 | Rxi Pharmaceuticals Corporation | Modified rnai polynucleotides and uses thereof |
WO2009137912A1 (en) | 2008-05-15 | 2009-11-19 | Topigen Pharmaceuticals Inc. | Oligonucleotides for treating inflammation and neoplastic cell proliferation |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
CN108165548B (zh) | 2008-09-22 | 2022-10-14 | 菲奥医药公司 | 减小大小的自递送RNAi化合物 |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
KR20180044433A (ko) | 2010-03-24 | 2018-05-02 | 알엑스아이 파마슈티칼스 코포레이션 | 진피 및 섬유증성 적응증에서의 rna 간섭 |
WO2011119852A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
EP2550001B1 (de) | 2010-03-24 | 2019-05-22 | Phio Pharmaceuticals Corp. | Rna-interferenz bei augenerkrankungen |
EP4269584A3 (de) * | 2011-08-11 | 2024-03-27 | Ionis Pharmaceuticals, Inc. | Selektive antisense-verbindungen und verwendungen davon |
CN106061488B (zh) | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
EP3137119B1 (de) | 2014-04-28 | 2020-07-01 | Phio Pharmaceuticals Corp. | Verfahren zur behandlung von krebs mithilfe von einer nukleinsaüre gegen mdm2 |
EP3188799B1 (de) | 2014-09-05 | 2022-07-06 | Phio Pharmaceuticals Corp. | Verfahren zur behandlung von alterung und hauterkrankungen mit auf tyr oder mmp1 gerichteten nukleinsäuren |
WO2017007825A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
WO2017007813A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
US20200030361A1 (en) * | 2016-09-23 | 2020-01-30 | City Of Hope | Oligonucleotides containing 2'-deoxy-2'fluoro-beta-d-arabinose nucleic acid (2'-fana) for treatment and diagnosis of retroviral diseases |
US20210040481A1 (en) * | 2018-03-19 | 2021-02-11 | The Trustees Of The University Of Pennsylvania | 2'f-ana-let7 mediated utrophin upregulation for dmd therapy |
US11254945B2 (en) * | 2018-07-06 | 2022-02-22 | The United States Of America, As Represented By The Secretary Of Agriculture | Targeted control of pests and pathogens by plant delivery of 2'F-ANA-oligonucleotides |
WO2020069044A1 (en) * | 2018-09-26 | 2020-04-02 | AUM LifeTech, Inc. | 2' fana modified foxp3 antisense oligonucleotides and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5194428A (en) * | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5004810A (en) * | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5955589A (en) * | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
US5135917A (en) * | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5985558A (en) * | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
AUPM516994A0 (en) * | 1994-04-20 | 1994-05-12 | Gene Shears Pty. Limited | An in vivo gene expression system |
US20010049436A1 (en) | 1998-04-01 | 2001-12-06 | Wen-Qiang Zhou | Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content |
ATE346918T1 (de) * | 1998-06-19 | 2006-12-15 | Univ Mcgill | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide |
US6277967B1 (en) * | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
WO2002020773A2 (en) | 2000-09-06 | 2002-03-14 | Mcgill University | Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
-
2003
- 2003-01-31 DK DK03700774T patent/DK1470144T3/da active
- 2003-01-31 CA CA2474414A patent/CA2474414C/en not_active Expired - Lifetime
- 2003-01-31 AT AT03700774T patent/ATE416183T1/de not_active IP Right Cessation
- 2003-01-31 ES ES03700774T patent/ES2318106T3/es not_active Expired - Lifetime
- 2003-01-31 AU AU2003202376A patent/AU2003202376B2/en not_active Ceased
- 2003-01-31 MX MXPA04007403A patent/MXPA04007403A/es active IP Right Grant
- 2003-01-31 NZ NZ534396A patent/NZ534396A/en not_active IP Right Cessation
- 2003-01-31 DE DE60325016T patent/DE60325016D1/de not_active Expired - Lifetime
- 2003-01-31 WO PCT/CA2003/000129 patent/WO2003064441A2/en active Application Filing
- 2003-01-31 EP EP03700774A patent/EP1470144B1/de not_active Expired - Lifetime
- 2003-01-31 PT PT03700774T patent/PT1470144E/pt unknown
- 2003-01-31 US US10/503,120 patent/US8278103B2/en active Active
- 2003-01-31 JP JP2003564061A patent/JP2005522997A/ja active Pending
-
2012
- 2012-08-30 US US13/599,520 patent/US9902953B2/en not_active Expired - Lifetime
-
2015
- 2015-09-08 US US14/847,873 patent/US20150368643A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1470144A2 (de) | 2004-10-27 |
NZ534396A (en) | 2006-11-30 |
US9902953B2 (en) | 2018-02-27 |
MXPA04007403A (es) | 2005-07-01 |
CA2474414A1 (en) | 2003-08-07 |
ES2318106T3 (es) | 2009-05-01 |
AU2003202376B2 (en) | 2008-10-30 |
PT1470144E (pt) | 2009-02-10 |
WO2003064441A3 (en) | 2003-10-02 |
US20130203977A1 (en) | 2013-08-08 |
WO2003064441A2 (en) | 2003-08-07 |
DK1470144T3 (da) | 2009-04-06 |
CA2474414C (en) | 2018-03-06 |
ATE416183T1 (de) | 2008-12-15 |
US8278103B2 (en) | 2012-10-02 |
US20050142535A1 (en) | 2005-06-30 |
US20150368643A1 (en) | 2015-12-24 |
JP2005522997A (ja) | 2005-08-04 |
EP1470144B1 (de) | 2008-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60325016D1 (de) | Oligonukleotide mit alternierenden segmenten und deren verwendungen | |
MXPA04004056A (es) | Oligonucleotidos que contienen enlazador aciclico y usos de los mismos. | |
WO2006047842A3 (en) | Modified nucleosides for rna interference | |
WO2003064625A3 (en) | Oligonucleotide compositions with enhanced efficiency | |
ATE154029T1 (de) | 7-deazapurin modifizierte oligonukleotide | |
WO2007134181A3 (en) | 5'-modified bicyclic nucleic acid analogs | |
WO2004066941A3 (en) | Expression profiles for colon cancer and methods of use | |
ES2118593T3 (es) | Analogos de nucleotidos de pteridina como sondas fluorescentes de adn. | |
DE69838449D1 (de) | Aminooxy-modifizierte oligonukleotide | |
DK1178999T3 (da) | L-RIBO-LNA-analoger | |
DK0731835T3 (da) | Antisense-oligonukleotider med tumorigenicitetshæmmende virkning | |
WO2007062160A8 (en) | Methods and compositions for sequencing a nucleic acid | |
PT1053313E (pt) | Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase | |
WO2005032495A3 (en) | Gene expression profiles and methods of use | |
WO2006112818A3 (en) | 3' modified oligonucleotides containing pseudoisocytosine nucleobase derivatives and applications thereof as primers or probes | |
ATE328074T1 (de) | Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten | |
WO2003101394A3 (en) | Defensins: use as antiviral agents | |
DE69815370D1 (de) | Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen | |
WO2006066154A3 (en) | Casein kinase 2 antisense therapy | |
NO965017D0 (no) | Oligonukleotider med anti-cytomegalovirus aktivitet | |
WO2003002587A3 (en) | Phosphoramide containing nucleic acid-based compounds and libraries as antivirals | |
WO1999066051A3 (en) | Nek-related and bub1-related protein kinases | |
Rusling et al. | Combining nucleoside analogues to achieve recognition of oligopurine tracts by triplex-forming oligonucleotides at physiological pH | |
WO2004071453A3 (en) | Compositions and methods for treatment of pouchitis | |
Belousoff et al. | Binding of HIV-1 TAR mRNA to a peptide nucleic acid oligomer and its conjugates with metal-ion-binding multidentate ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |